(VIANEWS) - Shares of BIOSENIC (BEL 20: BIOS.BR) jumped by a staggering 20.93% in 10 sessions from €0.11 to €0.13 at 20:10 EST on Wednesday, after three successive sessions in a row of gains. BEL 20 is falling 0.79% to €3,737.51, following the last session's downward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.43.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC's stock is considered to be oversold (<=20).
More news about BIOSENIC (BIOS.BR).